ASP 3662

Drug Profile

ASP 3662

Alternative Names: ASP-3662

Latest Information Update: 01 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Analgesics; Antidementias
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Diabetic neuropathies

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-II for Alzheimer's disease in USA (PO) (Astellas pipeline, July 2017)
  • 31 Jan 2017 Phase-II clinical trials in Alzheimer's disease in USA (PO) (Astellas Pharma pipeline, January 2017)
  • 26 Sep 2016 Updated pharmacodynamics data from preclinical studies in Diabetic neuropathies presented at the 16th World Congress of Pain-2016 (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top